WASHINGTON — Americans are already spending millions on CBD gummies and CBD lotions — but that’s chump change, at least if you ask the pharmaceutical companies betting that a CBD-based prescription medicine will ultimately be far more lucrative.
A number of pharmaceutical companies are shepherding their CBD-based products through the lengthy and expensive FDA approval process on exactly that bet — and some are further along than others.
About the Author Reprints
